NuGenerex Immuno-Oncology is looking for acquisitions and investment opportunities. As of June 17, 2020, the Company cash position is not sufficient for twelve months of operations. Generex has financed activities to date. The Company cash balances have been low throughout fiscal 2020. Management may seek to meet all or some of the Company operating cash flow requirements through financing activities, such as private placement of common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. In addition, management is actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities, and potential strategic partners.